Karin J. Metzner

University of Zurich

Switzerland

Research Interests

Explore related searches

Professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (16)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (9)

Michael Huber

Head Diagnostics and Development

University of Zurich

SWITZERLAND

View details

Fabian Otte

University of Basel

SWITZERLAND

View details

Dunja Nicca

University of Zurich

SWITZERLAND

View details

Roger D Kouyos

University Hospital of Zurich

SWITZERLAND

View details

Katharina Kusejko

University of Zurich

SWITZERLAND

View details

Andreas Plückthun

University of Zurich

SWITZERLAND

View details

Matthias Cavassini

SWITZERLAND

View details

A. Ramette

University of Bern

SWITZERLAND

View details

Huldrych Günthard

Professor, MD

University Hospital of Zurich

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Karin J. Metzner

Research Interests

Explore related searches

Contact this professor

Articles (16)

Correction: Schlösser et al. Anti-HIV-1 Effect of the Fluoroquinolone Enoxacin and Modulation of Pro-Viral hsa-miR-132 Processing in CEM-SS Cells. <i>Non-Coding RNA</i> 2025, <i>11</i>, 8

Anti-HIV-1 Effect of the Fluoroquinolone Enoxacin and Modulation of Pro-Viral hsa-miR-132 Processing in CEM-SS Cells

Self-reported neurocognitive complaints in the Swiss HIV Cohort Study: a viral genome-wide association study

Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy: the SIMPL’HIV open-label, factorial randomised controlled trial

Comparative Evaluation of Open-Source Bioinformatics Pipelines for Full-Length Viral Genome Assembly

Targeted shock-and-kill HIV-1 gene therapy approach combining CRISPR activation, suicide gene tBid and retargeted adenovirus delivery

Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018

Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks

Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial

Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periods

Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1

T-Cell Exhaustion in HIV-1/Hepatitis C Virus Coinfection Is Reduced After Successful Treatment of Chronic Hepatitis C

Transcriptome profiles of latently- and reactivated HIV-1 infected primary CD4+ T cells: A pooled data-analysis

Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials

Role of the HIV-1 Reservoir to Maintain Viral Suppression in a Simplified Strategy for the Long-Term Management of HIV-1 Infection (The SIMPL’HIV Trial)

An Approach to Quantifying the Interaction between Behavioral and Transmission Clusters

Collaborators (9)

Michael Huber

Fabian Otte

Dunja Nicca

Roger D Kouyos

Katharina Kusejko

Andreas Plückthun

Matthias Cavassini

A. Ramette

Huldrych Günthard

Make your next move.